Healthcare policy and cost news tracker: October 2026
Five policy threads are moving healthcare costs right now: ACA subsidies, Medicare drug prices, hospital price transparency, prior authorization, and GLP-1 cash pricing. Each one has a different status and a different action for you.
This is a cost tracker, not clinical advice. The changes below have different timelines: one subsidy enhancement has expired, negotiated Medicare prices begin next year, and some rules are already in effect while others remain proposals. Use the sections to identify which changes could affect your costs and what to verify before making a financial decision.
ACA enhanced premium tax credits expired — the subsidy cliff is back
Enhanced premium tax credits, extended through 2025 by the Inflation Reduction Act, expired on December 31, 2025 after Congress did not extend them, according to AJMC. As of the sources reviewed for this tracker, there is no later federal legislative status to report.
One consequence is the return of the “subsidy cliff.” Under the enhanced credits, people above 400% of the federal poverty level (FPL) became newly eligible for premium tax credits. Now, people above that threshold lose eligibility entirely, as Healthinsurance.org explains.
The budget risk is broader than the cliff alone. KFF estimated that, if the enhanced credits expired, average annual premium payments for subsidized enrollees would rise from $888 in 2025 to $1,904 in 2026, a 114% increase. The same KFF analysis reports that Marketplace enrollment has grown from about 11 million to over 24 million since the enhanced credits were introduced, and that the vast majority of enrollees receive an enhanced credit. The estimate is a forecast, not a record of each household’s actual premium change.
What to do differently: Log into your Marketplace account and re-estimate your 2027 premium before open-enrollment deadlines. If your income is above 400% FPL, expect to lose the premium subsidy entirely, so compare plans outside the Marketplace, including a broker or a spouse’s plan, and check whether an HSA-eligible high-deductible option is available to you.
Medicare drug price negotiation — IPAY 2027 prices arrive January 1
CMS negotiated maximum fair prices for 15 Part D drugs in the IPAY 2027 cycle. The negotiation period ended November 1, 2025, and the prices take effect January 1, 2027, according to the CMS fact sheet.
The next cycle is also underway. For IPAY 2028, CMS selected 15 drugs covered under Part B and/or Part D, plus one drug for renegotiation. CMS said on March 13, 2026 that all manufacturers agreed to participate. Negotiations take place in 2026, with prices effective in 2028. The CMS selected-drugs page has the cycle details.
What to do differently: If you take a Part D drug, check the CMS selected-drugs page to see whether it is on the IPAY 2027 list. If it is, ask your plan or pharmacist what the 2027 cost will be before you choose a Part D plan for next year.
Hospital price transparency — CY2026 enforcement began April 1
The CY2026 Outpatient Prospective Payment System/Ambulatory Surgical Center final rule made all hospital price transparency requirements effective January 1, 2026. Enforcement of the new and updated requirements began April 1, 2026, according to the CMS hospital price transparency page and its MLN fact sheet.
There is an important timing detail: CMS enforcement data says hospitals reviewed in the first quarter of 2026 were not assessed against the new requirements. CMS also lets consumers file a complaint when a hospital does not appear to post its prices. Separately, a Becker’s Hospital Review headline from October 6, 2026 reports that hospitals received warnings from the FTC and CMS in 2026 while penalties remained rare. This tracker did not read the article body, so that point rests on the headline alone.
What to do differently: Before a scheduled procedure, look for the hospital’s machine-readable price file or consumer price estimator. If the file is missing or broken, use the CMS complaint page.
Prior authorization — rules in force, drug coverage still pending
CMS-0057-F, the Interoperability and Prior Authorization Final Rule published January 17, 2024, requires impacted payers to implement FHIR application programming interfaces (APIs) and to streamline prior authorization. Impacted payers include Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid and CHIP managed care plans, and qualified health plan issuers on federally facilitated exchanges. The rule also adds an electronic prior-authorization measure for MIPS and the Medicare Promoting Interoperability Program, according to the CMS fact sheet.
The rule sets decision timeframes: impacted payers, excluding QHP issuers on the federally facilitated exchanges, must send prior authorization decisions within 72 hours for expedited (urgent) requests and seven calendar days for standard requests. Beginning in 2026, they must also give a specific reason for denials, except for drug decisions. The FHIR API requirements generally begin January 1, 2027, according to the same CMS fact sheet.
Drug coverage is a separate, unfinished issue. CMS-0062-P, released in 2026, is a proposed rule, not a final rule. It would extend electronic prior authorization and shorter decision timeframes to drugs, and increase transparency for drug prior authorization. The public comment period closed June 15, 2026, according to CMS.
What to do differently: For a pending prior authorization, calendar the decision deadline printed on the plan’s notice and follow up in writing if it passes. If the request is denied, ask for the specific denial reason. Do not count on CMS-0062-P for drug coverage changes yet; it is not final.
GLP-1 cash prices and TrumpRx — what’s verified and what isn’t
TrumpRx.gov, a federal referral site launched in 2026, lists drug cash prices with Most-Favored-Nation framing. Its website is the place to check current listings.
A third-party tracker gives some figures, but they are unverified: this tracker did not read per-drug prices directly from TrumpRx, which renders them with JavaScript. As listed by a third-party tracker as of September 2026, the figures are: Wegovy pill, $149 per month; Wegovy pen, $199 per month for the first two fills of the 0.25 mg and 0.5 mg strengths and then $349 per month; Ozempic pen, the same structure; and Zepbound vial, $299 per month. These figures come from trytrimi.com, not from direct verification of the federal site. Treat them as unverified until you see the price on TrumpRx itself.
For the separate Medicare GLP-1 Bridge program, see the existing Medicare GLP-1 Bridge program cost guide.
What to do differently: Before paying cash for a GLP-1, check TrumpRx.gov and compare its current listing with the third-party figures above. Do not treat a third-party price as confirmed until you verify it on the federal site.
What to do this week
- Re-estimate Marketplace costs. If your income is above 400% FPL, review your Marketplace account before open-enrollment deadlines. If you are above the cliff, compare off-Marketplace options and HSA-eligible high-deductible plans.
- Check the IPAY 2027 list. Look up any Part D drugs you take on the CMS selected-drugs page. If a drug is listed, ask your plan or pharmacist about its negotiated 2027 price.
- Check hospital prices before a scheduled procedure. Pull the hospital’s machine-readable file or consumer price estimator; if it is missing or broken, file a complaint with CMS.
- Calendar prior-authorization deadlines. Urgent requests should get a decision within 72 hours and standard requests within seven calendar days, unless your plan is a QHP issuer on a federally facilitated exchange. If a deadline passes, follow up in writing; if denied, ask for a specific reason.
- Verify any GLP-1 cash price. Check TrumpRx.gov directly and treat third-party tracker figures as unverified.
| Thread | Status | Effective date | Who it affects | Reader action |
|---|---|---|---|---|
| ACA enhanced credits | Expired Dec. 31, 2025 (AJMC) | 2026 plan year | Marketplace enrollees, especially above 400% FPL (Healthinsurance.org) | Re-estimate subsidy; price off-Marketplace options |
| IPAY 2027 prices | Negotiated (CMS) | Jan. 1, 2027 (CMS) | Part D enrollees on listed drugs | Check CMS list; ask plan about 2027 price |
| IPAY 2028 cycle | In negotiation during 2026 (CMS) | 2028 (CMS) | Part B and/or Part D users | Watch CMS selected-drugs page |
| Hospital transparency | Enforced since Apr. 1, 2026 (CMS) | Jan. 1, 2026 rules; Apr. 1, 2026 enforcement (CMS) | Anyone comparing hospital prices | Pull price file; file CMS complaint if missing |
| CMS-0057-F | Final rule, published Jan. 17, 2024 (CMS) | API requirements generally begin Jan. 1, 2027 (CMS) | MA, Medicaid/CHIP, and QHP enrollees | Calendar 72-hour (urgent) or 7-day (standard) decision windows |
| CMS-0062-P | Proposed, not final (CMS) | Not set | Drug prior-authorization patients | Do not rely on it yet |
| GLP-1 / TrumpRx | Live; prices unverified (TrumpRx.gov, third-party tracker) | 2026 launch (TrumpRx.gov) | Cash-pay GLP-1 buyers | Verify price on TrumpRx.gov yourself |
FAQ
I’m above 400% FPL. Do I get any subsidy now?
People above 400% FPL lose eligibility for premium tax credits now that the enhanced credits have expired, as Healthinsurance.org describes. Check your Marketplace account and compare other plan options.
When do negotiated Medicare drug prices start?
IPAY 2027 maximum fair prices take effect January 1, 2027, according to CMS.
Are hospitals being penalized for noncompliant price files?
CMS began enforcing new and updated requirements on April 1, 2026, but hospitals reviewed in the first quarter were not assessed against them, according to CMS enforcement data. A Becker’s headline reports that penalties remained rare. You can file a complaint with CMS.
Is the prior-authorization rule for drugs in effect?
No. CMS-0062-P is a proposed rule, not final, according to CMS.
The Bottom Line
Marketplace subsidies shrank when the enhanced credits expired, and negotiated Medicare prices arrive in January. Hospital transparency rules are being enforced, but consumers need to use price files and complaint channels to act on them. GLP-1 cash prices reported by a third-party tracker remain unverified, so check TrumpRx directly. The highest-leverage action this week is to re-estimate your Marketplace premium before open-enrollment deadlines.
How This Guide Was Built
Sources: CMS pages, KFF, AJMC, and Healthinsurance.org, fetched October 19, 2026. This tracker was compiled from official documentation and reporting; we did not run any tools or services hands-on.
Verification gaps: the Becker’s article body was not retrieved because of an anti-bot block, so its headline is cited only as reporting. The TrumpRx.gov text retrieved did not show these per-drug prices (the site renders prices with JavaScript), so the figures above are labeled third-party and unverified. No 2026 federal ACA legislative status beyond “expired Dec. 31, 2025; not extended as of sources fetched” is reported here. The prior-authorization timeframes above are as stated in the CMS fact sheet.